KCKaren-Sue Carlson

Karen-Sue Carlson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Karen-Sue Carlson has a total of 145 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy

    by Ariel Kleman, Arun Singavi, Lauren Pommert, Angela J. Mathison, Parameswaran Hari, Binod Dhakal, Meera Mohan, Siegfried Janz, Jennifer M. Knight, Mithun V. Shah, et al.


  • Open Access

    Mutant CALR’s “sweet tooth”

    by Sridhar Rao, Karen Carlson

    In this issue of Blood, Jutzi et al1 present compelling evidence of glycosylation as a potential therapeutic vulnerability in calreticulin (CALR)-mutated myelop

  • Open Access

    Revisiting biochemistry: severe euglycemic ketoacidosis in the setting of IDH‐inhibitor therapy for AML

    by Marium Khan, John T. Roddy, Jesus R. Hernandez, Karina Bursch, Naveet Bal, Karen S. Carlson, Paul A. Bergl


  • Improving Outcomes of Acute Promyelocytic Leukemia in the Current Era: Analysis of the SEER Database

    by Guru Subramanian Guru Murthy, Aniko Szabo, Laura Michaelis, Karen-Sue Carlson, Lyndsey Runaas, Sameem Abedin, Ehab Atallah

    Background: Outcomes of acute promyelocytic leukemia (APL) have significantly improved with the availability of targeted agents. It remains unclear whether the population-level outcomes of APL have improved over time. Methods: Using the SEER database, we identified patients aged >= 20 years with pathologically confirmed APL diagnosed in 2000 through 2014 and who were actively followed. Patients were stratified by diagnosis period into 3 groups (2000-2004, 2005-2009, and 2010-2014) to assess the temporal trends in overall survival (OS), cause-specific survival (CSS), and other outcomes. Results: A total of 2,962 patients with a median age of 48 years (range, 20-96 years) were included. Hispanic patients constituted 21.5% of the cohort and the largest proportion (47.9%) of uninsured patients. The incidence of APL was 0.33 cases per 100,000 population per year. Incidence varied significantly by age, sex, race/ethnicity, and diagnosis period. Survival was significantly higher for patients diagnosed in 2010 through 2014 compared with those diagnosed in 2005 through 2009 and in 2000 through 2004 (4-year OS, 73.4% vs 65.6% vs 57.3%, respectively; 4-year CSS, 78.3% vs 70.8% vs 60.8%, respectively). Early mortality improved significantly over time (2000-2004, 25.3%; 2005-2009, 20.6%; 2010-2014, 17.1%) and was higher in men and Hispanic patients. According to multivariate analysis, diagnosis before 2010 and unmarried status were associated with a higher mortality risk. Uninsured patients had a significantly higher early mortality without a significant difference in post-30-day CSS. No significant changes were noted in risk of secondary malignancies. Conclusions: Population-level outcomes of APL have continued to improve over time. However, significant discrepancies in disease outcomes continue to exist, highlighting the need for more research.


  • Open Access

    The Adult Murine Intestine is Dependent on Constitutive Laminin-γ1 Synthesis

    by British Fields, Ann DeLaForest, Mark Zogg, Jennifer May, Catherine Hagen, Kristin Komnick, Jon Wieser, Alexander Lundberg, Hartmut Weiler, Michele A. Battle, et al.

    Laminin-γ1 is required for early embryonic development; however, the need for laminin-γ1 synthesis in adulthood is unknown. A global and inducible mouse model of laminin-γ1 deficiency was generated to address this question. Genetic ablation of the Lamc1 gene in adult mice was rapidly lethal. Despite global Lamc1 gene deletion in tamoxifen-induced mutant mice, there was minimal change in total cardiac, pulmonary, hepatic or renal laminin protein. In contrast, laminin-γ1 was significantly depleted in the small intestines, which showed crypt hyperplasia and dissociation of villous epithelium from adjacent mesenchyme. We conclude that the physiologic requirement for laminin-γ1 synthesis in adult mice is dependent on a tissue-specific basal rate of laminin-γ1 turnover that results in rapid depletion of laminin-γ1 in the intestine.


  • Role of thrombomodulin expression on hematopoietic stem cells

    by Sreemanti Basu, Hai Po Helena Liang, Irene Hernandez, Mark Zogg, British Fields, Jennifer May, Yamini Ogoti, Tine Wyseure, Laurent O. Mosnier, Robert T. Burns, et al.


  • Open Access

    Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome

    by Chao Yang, Jason R. Siebert, Robert Burns, Zachary J. Gerbec, Benedetta Bonacci, Amy Rymaszewski, Mary Rau, Matthew J. Riese, Sridhar Rao, Karen-Sue Carlson, et al.

    Natural killer (NK) cells are critical to both innate and adaptive immunity. However, the development and heterogeneity of human NK cells are yet to be fully defined. Using single-cell RNA-sequencing technology, here we identify distinct NK populations in human bone marrow and blood, including one population expressing higher levels of immediate early genes indicative of a homeostatic activation. Functionally matured NK cells with high expression of CX3CR1, HAVCR2 (TIM-3), and ZEB2 represents terminally differentiated status with the unique transcriptional profile. Transcriptomic and pseudotime analyses identify a transitional population between CD56bright and CD56dim NK cells. Finally, a donor with GATA2T354M mutation exhibits reduced percentage of CD56bright NK cells with altered transcriptome and elevated cell death. These data expand our understanding of the heterogeneity and development of human NK cells.


  • Critical role of Jumonji domain of JMJD1C in MLL-rearranged leukemia

    by Jesus Izaguirre-Carbonell, Luke Christiansen, Robert Burns, Jesse Schmitz, Chenxuan Li, Rebekah L. Mokry, Theresa Bluemn, Yongwei Zheng, Jian Shen, Karen-Sue Carlson, et al.

    JMJD1C, a member of the lysine demethylase 3 family, is aberrantly expressed in mixed lineage leukemia (MLL) gene-rearranged (MLLr) leukemias. We have shown previously that JMJD1C is required for self-renewal of acute myeloid leukemia (AML) leukemia stem cells (LSCs) but not normal hematopoietic stem cells. However, the domains within JMJD1C that promote LSC self-renewal are unknown. Here, we used clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein-9 nuclease (Cas9) negative-selection screening and identified a requirement for the catalytic Jumonji (JmjC) domain and zinc finger domain for leukemia cell survival in vitro and in vivo. In addition, we found that histone H3 lysine 36 methylation (H3K36me) is a marker for JMJD1C activity at gene loci. Moreover, we performed single cell transcriptome analysis of mouse leukemia cells harboring a single guide RNA (sgRNA) against the JmjC domain and identified increased activation of RAS/MAPK and the JAK-STAT pathway in cells harboring the JmjC sgRNA. We discovered that upregulation of interleukin 3 (IL-3) receptor genes mediates increased activation of IL-3 signaling upon JMJD1C loss or mutation. Along these lines, we observed resistance to JMJD1C loss in MLLr AML bearing activating RAS mutations, suggesting that RAS pathway activation confers resistance to JMJD1C loss. Overall, we discovered the functional importance of the JMJD1C JmjC domain in AML leukemogenesis and a novel interplay between JMJD1C and the IL-3 signaling pathway as a potential resistance mechanism to targeting JMJD1C catalytic activity.


  • Early Fluorescence in situ Hybridization Assessment during Acute Myeloid Leukemia Induction Chemotherapy

    by Robert Schneidewend, Paul Hosking, Ruta Brazauskas, Jess Peterson, Carlie Beaudin, Laura Michaelis, Ehab Atallah, Parameswaran Hari, Karen Carlson

    The standard of care for upfront remission induction therapy for “fit” adults with de novo acute myeloid leukemia (AML) is continuous-infusion cytarabine with concurrent anthracycline (i.e., “7+3” regimen) [1]. Fourteen days after the initiation of chemotherapy, bone marrow is re-evaluated to identify patients who may benefit from immediate receipt of an additional cycle of remission induction chemotherapy. Current NCCN guidelines specify that a second cycle of induction chemotherapy should be administered prior to count recovery if (1) more than 5% of the cells in the day-14 bone marrow sample are morphologically consistent with myeloblasts and (2) the clinical status of the patient permits safe administration of cytotoxic therapy [2].